Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
17.89
+1.35 (8.16%)
Mar 31, 2026, 4:00 PM EDT - Market closed
Aktis Oncology Stock Forecast
Stock Price Forecast
The 2 analysts that cover Aktis Oncology stock have a consensus rating of "Strong Buy" and an average price target of $31.5, which forecasts a 76.08% increase in the stock price over the next year. The lowest target is $30 and the highest is $33.
Price Target: $31.5 (+76.08%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aktis Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $33 | Strong Buy | Maintains | $30 → $33 | +84.46% | Mar 31, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +67.69% | Mar 9, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $30 | Buy | Initiates | $30 | +67.69% | Feb 3, 2026 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $2 → $1 | Buy → Hold | Downgrades | $2 → $1 | -94.41% | Jan 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $6 → $3 | Buy | Maintains | $6 → $3 | -83.23% | Sep 7, 2023 |
Financial Forecast
Revenue This Year
16.69M
from 6.50M
Increased by 156.84%
Revenue Next Year
18.12M
from 16.69M
Increased by 8.60%
EPS This Year
-1.28
EPS Next Year
-1.66
from -1.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 52.5M | 36.8M |
| Avg | 16.7M | 18.1M |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 708.1% | 120.2% |
| Avg | 156.8% | 8.6% |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -0.84 | -1.48 |
| Avg | -1.28 | -1.66 |
| Low | -1.52 | -1.80 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.